$OEG I will be back in if Q3 ER is good. The pandemic benefit extension was ended September 30th, people begin to take jobs like installers. So they would have adequate level of staffs before Q3 ER. That may help to beat the revs forecast, likley $33m? Otherwise, will have to wait for Q4 er in February. Understaff with mountain high backlogs is the challenge that everyone sees it. But the real challenge hindering share prices is 1. overhanging shelf, 2. without a positive EBITDA and 3. underdelivery in the past 3Q, making OEG enthusiasts like me hesitant to buy big. But I am sure it will improves over time. The backlogs if realized, points to a PT $17 with further dilution and $27 without.